{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"21.65","value":"8.28"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"}],"units":"Participants"}],"description":"Time To Progression was defined as the duration from the date of the first study drug dose to the date of progression (PD). In this analysis, pts who did not progress were censored at their last evaluation with an OPDREC assessment.","dispersionType":"Full Range","groups":[{"description":"Regimen was 14 mg/m2 IV over a 4-hour period on Days 1, 8, and 15 of a 28-day cycle. The protocol included 6 cycles of treatment; responding patients and patients who achieved at least Stable Disease (SD) had the option of continuing treatment beyond 6 cycles at the discretion of the Investigator and based on local regulations.","id":"OG000","title":"Romidepsin"}],"paramType":"MEDIAN","populationDescription":"Efficacy analysis based on interim analysis of data for as treated population","reportingStatus":"POSTED","timeFrame":"Up to 10 months; median duration of follow up was 6.1 months","title":"Time to Disease Progression","type":"SECONDARY","unitOfMeasure":"Months"}